Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients

Pazopanib is an angiostatic tyrosine kinase inhibitor (TKI) presently used for cancer treatment, particularly in patients with renal cell carcinoma (RCC). This treatment can be accompanied by mild bleeding as an adverse effect. Given the role of protein tyrosine kinases in platelet activation proces...

Descripción completa

Detalles Bibliográficos
Autores principales: Tullemans, Bibian M. E., Nagy, Magdolna, Sabrkhany, Siamack, Griffioen, Arjan W., oude Egbrink, Mirjam G. A., Aarts, Maureen, Heemskerk, Johan W. M., Kuijpers, Marijke J. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232667/
https://www.ncbi.nlm.nih.gov/pubmed/30460241
http://dx.doi.org/10.3389/fcvm.2018.00142

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6232667/
https://www.ncbi.nlm.nih.gov/pubmed/30460241
http://dx.doi.org/10.3389/fcvm.2018.00142

Ejemplares similares